MS 222 Pharmaq

Main information

  • Trade name:
  • MS 222 Pharmaq
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • MS 222 Pharmaq
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Tricaine mesilate
  • Therapeutic area:
  • Fish

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0405/001
  • Authorization date:
  • 21-11-2012
  • EU code:
  • UK/V/0405/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

IssuedFebruary2013

AN:01919/2011

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

TricainePharmaq1000mg/gPowderforSolutionforFishTreatment

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

ActiveSubstance:

Qualitativecomposition Quantitativecomposition

TricaineMethaneSulphonate 1000mg/g

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Powderforsolutionforfishtreatment.

Whitetooff-whitepowder.

4. CLINICALPARTICULARS

4.1Targetspecies

1)Ornamentalfish,ortheirdevelopmentstages,and

2)Breedingandjuvenilestagesoffish.

4.2Indicationsforuse,specifyingthetargetspecies

Foruseinanimmersionbathforsedation,immobilisationandanaesthesiaoffishfor:

vaccination,transportation,weighing,tagging,clipping,strippingofbreedstock,

blood-samplingandsurgicalprocedures.

4.3Contraindications

Theproductshouldnotbeusedinthefollowingtropicalfishspecies:

Apistogramma(Mikrogeophagus)ramirez,Balantiocheilosmelanopterus,Etroplus

suratensis,Melanotaeniamaccullochi,Monodactylusargenteus,Phenacogrammus

interruptusandScatophagusargus

4.4Specialwarningsforeachtargetspecies

None

IssuedFebruary2013

AN:01919/2011

Page2of7

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Donotexceedthedoserecommendedforeachcategoryoffish.

Broodstockanaesthetisedforstrippingshouldbeimmersedin

unmedicatedwaterimmediatelybeforecollectionofeggsormilttoavoid

significantdirectcontactofeitherwiththeproduct.

Assolutionsoftheveterinarymedicinalproductareslightlyacidic,theuse

ofphosphateorimidazolbufferhasbeenproposedtoreducestress.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Ifyouknowyouarehypersensitive(allergic)toanaestheticssuchas

Tricainemesilate(Tricainemethanesulphonate),donothandlethe

product.

Donotcreatedustwhenhandlingthepowderorpreparingtheanaesthetic

solution.Incaseofaccidentalinhalationofdust,movetofreshairandif

breathingisaffected,seekmedicaladviceimmediatelyandshowthe

doctortheproductlabel.Insituationswheredustiscreatedwhenhandling

thepowder,wearadisposablehalfmaskrespiratorconformingto

EuropeanStandardEN149oranon-disposablerespiratortoEuropean

StandardEN140withafiltertoEN143.

Wearimpermeablerubbergloveswhenhandlingtheproductorsolution.

Avoidcontactwithskinandeyes.Incaseofaccidentalcontact,

immediatelywashtheaffectedareawithplentyofcleanrunningwater.If

irritationpersists,seekmedicaladvice.

Donoteat,drinkorsmokewhilsthandlingthisproduct.

Washhandsafteruse.

Incaseofaccidentalingestion,seekmedicaladviceimmediatelyand

showthepackageleafletorthelabeltothephysician.

Otherprecautions

Inordertoprotecttheenvironment,usedsolutionmusteitherbefiltered

usingactivatedcharcoalfilterspriortodilutionintheeffluenttobe

dischargedfromthefarmoritmustbetransferredtoaholdingtank

filledwithwaterwithsubsequentcontrolledreleasefordilutioninthe

effluenttobedischargedfromthefarm.Seesection6.6.

IssuedFebruary2013

AN:01919/2011

Page3of7

4.6Adversereactions(frequencyandseriousness)

Noneknown.

4.7Useduringpregnancy,lactationorlay

Notapplicable.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

TricaineMethaneSulphonatehasbeenusedsuccessfullyatlowerconcentrationsin

conjunctionwithseveralotheranaesthetics.Noadverseinteractionwithother

pharmaceuticalshasbeenestablished.

4.9Amountstobeadministeredandadministrationroute

Anaqueoussolutionoftheproductisusedinanimmersionbathforsedation,

immobilisationandanaesthesiaoffish,bothornamentalandthoseintendedfor

humanconsumption.

Anumberoffactorsinfluencetheefficacyandsafetyoftheproduct,including

concentrationofthedruginwater,durationofexposure,temperature,oxygencontent

anddensityofbiomass.Becauseofthesevariablefactorsitisstronglyrecommended

thatatestoftheselecteddrugconcentrationandexposuretimeisconductedwitha

smallgroupofrepresentativefishbeforelargenumbersaremedicated.Thisis

especiallyimportantwhenwatertemperatureisattheupperorlowerendsofthe

normaltemperaturerangesforthespeciesbeingtreated.Theproductshouldbe

dissolvedinwaterofthesamecompositionandcharacteristicsasthattowhichthe

fishareaccustomed.Astheproducthasgoodaqueoussolubility,itmaybeadded

directlytothecontainer.Effectsonthefishshouldbemonitoredastheproductis

graduallyintroduced.

Beforeanaesthesia,orprolongedsedation,fishshouldbefastedfor12to24hours.

Duringtreatmenttheyshouldbestockedatadensitynotexceeding80g/litre.To

minimisedamageandlosswhenmedicatedforlongperiodsfortransportetc.the

levelofsedationshouldallowfishtomaintaintheirequilibriumandswimming

position.Aerationshouldbeprovidedunlesssedation,oranaesthesia,isofshort

duration.Inanaesthesialossofreflexestakesplaceinonetofifteenminutesafter

immersiondependinguponconcentrationemployed.Narcotisedfishshouldbe

removedfrommedicatedwaterandreturnedtotheirnormalenvironmentassoonas

possible,whenrecoverywilltakebetweenoneandthirtyminutes.

IssuedFebruary2013

AN:01919/2011

Page4of7

Thefollowingexamplesofdoseratesandexposuretimesarebasedonlaboratory

andfieldexperience:

Concentration

mg/litreof

water Immersion

time(mins)

Troutspecies(7-

17ºC)

Sedation 10-30 Upto480

Anaesthesia Light

Deeper 30-80

80-180 Upto30

Upto10

Salmonspecies

Sedation 7-30 Upto240

Anaesthesia Light

Deeper 30-80

80-100 Upto10

Upto5

Bassspecies

Sedation 8-30 Upto480

Anaesthesia Light

Deeper 30-70

70-100 Upto20

Upto4

Carpspecies

Sedation 20-30 Upto1440

Anaesthesia 30-200 Upto8

Freshwatertropicalfish

Sedation 30-50 Upto1440

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Removefishimmediatelytoaeratedwaterofthesamecompositionandtemperature

thatisfreefromanaesthetic.Overdoseorprolongedexposuretotheproductmay

causerespiratoryfailureanddeath.

4.11Withdrawalperiod(s)

Fishmustnotbeslaughteredforhumanconsumptionduringtreatment.

Fishcanonlybeharvestedforhumanconsumption70degreedaysafterthe

lasttreatment.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Anaesthetics,general,othergeneralanaesthetics

ATCvetcode:QN01AX93

5.1Pharmacodynamicproperties

Tricainemethanesulphonatehaspropertiesslightlydifferentfrom,butsimilarto,both

esterandamideanaesthetics,actingasageneralanaestheticornarcotic.Itismore

water-solublethanBenzocaine,lendingittofishapplication.Fisharenormally

IssuedFebruary2013

AN:01919/2011

Page5of7

immersedinsolutionsandbothabsorptionandexcretionoccurthroughthegill

epithelium.

Thedrugcausesreducedbloodflowthroughthegillsandreducedoxygen

consumption.Therateatwhichnarcosisisinduceddependsupontheconcentration

oftheproductinwaterandalsouponthewatertemperature.Athighertemperatures

onsetornarcosisismorerapid;howeverthesafetymarginisless.Immersionoffish

inunmedicatedwaterreversesnarcoticeffects.

5.2Pharmacokineticparticulars

Tricainemethanesulphonateissolubleinlipids,whichprobablyaccountsforitsrapid

diffusionacrossgillsinbothdirections,withrapidanaesthesiaandrapidrecovery.

Thedrugisdistributedthroughoutthebody.

Excretionoccursmainlyacrossthegillepithelium.Non-polarethylmeta-

aminobenzoateanditsN-acetylderivativearebothexcretedacrossthegills,

whereasthepolarmeta-aminobenzoicacidanditsN-acetylderivativeareexcreted

viathekidneys.Allspeciestestedappeartoproduceanacetylatedderivative,tothe

extentnormallyoflessthan20%oftheoriginalanaesthetic.Thehydrolysisto

producethefreeacidalsovarieswithspecies,sokidneyexcretionwillvarybetween

species.However,theeffectivenessvarieslessbetweenspeciesowingtothefree

movementofthedrugacrossthegills.

Theconcentrationinsalmonidmuscle,whilstthefishisunderanaesthetic,ranges

from9.4to72.0mg/kg.Thehalflifeoftheanaestheticinmuscleonwithdrawalis

approximately70minutes.Thus24hoursgives20halflives.Thehighest

concentrationsfoundinsalmonidmuscleafter24hourshavebeen2.6to3.2mg/kg

(theoralLDina30kgdogis30,000x4mgoftheanaesthetic).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

None.

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelflifeafterdilutionorreconstitutionaccordingtodirections:24hours.

IssuedFebruary2013

AN:01919/2011

Page6of7

6.4.Specialprecautionsforstorage

Storeintheoriginalcontainer.

Storeinadryplace.

Keepthecontainertightlyclosedinordertoprotectfrommoisture.

Protectsolutionfromdirectsunlight.

6.5Natureandcompositionofimmediatepackaging

HighDensityPolyethylene(HDPE)tamperresistanttubsclosedwithandintegral,

tamperevident,lowdensitypolyethylenecap(snapon)containingeither25g,100g,

250gor1000g.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Usedsolutionmusteitherbefilteredusingactivatedcharcoalfilterspriorto

dilutionintheeffluenttobedischargedfromthefarmoritmustbetransferredtoa

holdingtankfilledwithwaterwithsubsequentcontrolledreleasefordilutionin

theeffluenttobedischargedfromthefarm.

Filtration

Filtrationofusedsolutionthroughanactivatedcharcoalfilterwillensurethatthe

concentrationofspenttricainemethanesulphonateindischargewaterdoesnot

exceed1µg/L.Spentcarbonfiltersshouldbedisposedofinaccordancewithlocal

requirements

Holdingtank

Transferofusedsolutiontoaholdingtankfilledwithwaterandcontrolledreleasefor

dilutionintheeffluentwillensurethattheconcentrationofspenttricainemethane

sulphonateindischargewaterdoesnotexceed1µg/Lwhenreleasingthesolution

fromtheholdingtankatflowratescalculatedinthetablebelow(1000Land50000L

holdingtanks).Dischargeflowsfordifferentsizedholdingtankscanbecalculatedas

showninthe50000Lcolumn.

Farmflowrate(L/min) Dischargeflow(L/h)fromholdingtank

1000Lholdingtank 50000Lholdingtank

10000-14999 15 (50*15) 750

15000-19999 22 (50*22)1100

20000-24999 30 (50*30)1500

25000-29999 37 (50*37)1850

30000-35000 45 (50*45)2250

Anyunusedveterinarymedicinalproductshouldbedisposedofinaccordancewith

nationalrequirements.

IssuedFebruary2013

AN:01919/2011

Page7of7

7. MARKETINGAUTHORISATIONHOLDER

PharmaqLimited

Unit15

SandleheathIndustrialEstate

Fordingbridge

HampshireSP61PA

UnitedKingdom

8. MARKETINGAUTHORISATIONNUMBER

Vm11003/4014

9. DATEOFFIRSTAUTHORISATION

07February2013

10.DATEOFREVISIONOFTHETEXT

February2013

Approved: 07/02/2013

30-11-2018

Reporting Avian Influenza surveillance

Reporting Avian Influenza surveillance

Published on: Thu, 29 Nov 2018 Avian influenza viruses infect domestic poultry and wild birds as well as humans. In poultry, depending on whether these viruses are of high pathogenicity (HPAI) or low pathogenicity (LPAI), the infection can cause different clinical signs, with HPAI causing high mortality in poultry flocks. In order to ensure early detection of avian influenza viruses, surveillance in poultry and wild birds is considered essential. In 2010, the European Commission provided some guidelines...

Europe - EFSA - European Food Safety Authority Publications

29-11-2018

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

The U.S. Food and Drug Administration (FDA) is warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab).

FDA - U.S. Food and Drug Administration

20-11-2018

Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine

Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine

FDA is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than before the medicine was started or while it was being taken. This MS worsening is rare but can result in permanent disability.

FDA - U.S. Food and Drug Administration

11-5-2018

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

FDA approves Gilenya (fingolimod) to treat multiple sclerosis MS in children age 10 and older. This is the first FDA approval of a drug to treat MS in pediatric patients

FDA - U.S. Food and Drug Administration

1-10-2018

MS-H vaccine (Pharmsure Veterinary Products Europe Ltd)

MS-H vaccine (Pharmsure Veterinary Products Europe Ltd)

MS-H vaccine (Active substance: Mycoplasma synoviae Strain MS-H live attenuated thermosensitive) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6404 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/161/T/11

Europe -DG Health and Food Safety

24-9-2018

Karvezide (Sanofi-Aventis groupe)

Karvezide (Sanofi-Aventis groupe)

Karvezide (Active substance: Irbesartan / hydrochlorothiazide) - Centralised - Yearly update - Commission Decision (2018)6222 of Mon, 24 Sep 2018

Europe -DG Health and Food Safety

1-8-2018

Eylea (Bayer AG)

Eylea (Bayer AG)

Eylea (Active substance: aflibercept) - Centralised - 2-Monthly update - Commission Decision (2018)5222 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2392/II/45

Europe -DG Health and Food Safety

1-8-2018

Enbrel (Pfizer Europe MA EEIG)

Enbrel (Pfizer Europe MA EEIG)

Enbrel (Active substance: Etanercept) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5195 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/262/T/222

Europe -DG Health and Food Safety

1-8-2018

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Active substance: Meningococcal group A, C, W-135 and Y conjugate vaccine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5220 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2226/T/80

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/2005 (IQVIA RDS Ireland Limited)

EU/3/18/2005 (IQVIA RDS Ireland Limited)

EU/3/18/2005 (Active substance: Tazemetostat) - Orphan designation - Commission Decision (2018)1893 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/222/17

Europe -DG Health and Food Safety

11-1-2018

GALLIPRANT (Elanco GmbH)

GALLIPRANT (Elanco GmbH)

GALLIPRANT (Active substance: grapiprant) - New authorisation - Commission Decision (2018)144 of Thu, 11 Jan 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4222

Europe -DG Health and Food Safety